Biogen (BIIB) Stock: $219 Price Target And Equal-Weight Rating

By Amit Chowdhry ● Apr 15, 2022
  • The shares of Biogen Inc (NASDAQ: BIIB) have received a $219 price target from Barclays. These are the details.

The shares of Biogen Inc (NASDAQ: BIIB) have received a $219 price target from Barclays. And Barclays analyst Carter Gould is maintaining an “Equal-Weight” rating on the shares.

Gould noted that the first quarter prints are unlikely going to disrupt the momentum of macro-driven rotation to larger cap biopharma.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.